| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 125.43% | Goldman Sachs | $3 → $0.5 | Maintains | Sell |
| 11/09/2023 | — | Evercore ISI Group | Downgrades | Outperform → In-Line | |
| 11/09/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 11/09/2023 | 350.86% | Mizuho | $31 → $1 | Downgrades | Buy → Neutral |
| 09/26/2023 | 12523.99% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 08/21/2023 | 531.2% | Citigroup | $2 → $1.4 | Maintains | Sell |
| 08/09/2023 | 11171.42% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 06/14/2023 | 12523.99% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 05/09/2023 | 8917.13% | Canaccord Genuity | $50 → $20 | Maintains | Buy |
| 02/09/2023 | 11171.42% | EF Hutton | → $25 | Reiterates | → Buy |
| 02/09/2023 | 12073.13% | HC Wainwright & Co. | $29 → $27 | Maintains | Buy |
| 02/07/2023 | 13876.56% | Mizuho | → $31 | Reiterates | → Buy |
| 01/05/2023 | 11171.42% | EF Hutton | → $25 | Initiates Coverage On | → Buy |
| 08/16/2022 | 13876.56% | Mizuho | $39 → $31 | Maintains | Buy |
| 08/09/2022 | 1252.57% | Goldman Sachs | $4 → $3 | Maintains | Sell |
| 07/20/2022 | 1252.57% | Citigroup | → $3 | Downgrades | Neutral → Sell |
| 07/13/2022 | 4408.57% | JP Morgan | → $10 | Downgrades | Overweight → Neutral |
| 07/13/2022 | 2154.28% | Stifel | $16 → $5 | Downgrades | Buy → Hold |
| 05/24/2022 | 1703.43% | Goldman Sachs | $5 → $4 | Maintains | Sell |
| 05/23/2022 | 12974.84% | HC Wainwright & Co. | $31 → $29 | Maintains | Buy |
| 05/10/2022 | 3506.85% | Citigroup | $23 → $8 | Downgrades | Buy → Neutral |
| 03/28/2022 | 9818.85% | JP Morgan | $27 → $22 | Maintains | Overweight |
| 01/03/2022 | 12073.13% | JP Morgan | $26 → $27 | Maintains | Overweight |
| 05/13/2021 | 12974.84% | JP Morgan | $23 → $29 | Upgrades | Neutral → Overweight |
| 05/05/2021 | 13876.56% | HC Wainwright & Co. | $32 → $31 | Maintains | Buy |
| 12/08/2020 | 13876.56% | HC Wainwright & Co. | $28 → $31 | Maintains | Buy |
| 11/10/2020 | 12523.99% | HC Wainwright & Co. | $26 → $28 | Maintains | Buy |
| 09/15/2020 | 35066.82% | Canaccord Genuity | $70 → $78 | Maintains | Buy |
| 08/06/2020 | 12523.99% | Stifel | $30 → $28 | Maintains | Buy |
| 08/06/2020 | 11622.27% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 06/30/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/15/2020 | 11171.42% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 05/12/2020 | 10269.7% | JP Morgan | $22 → $23 | Maintains | Neutral |
| 04/23/2020 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/08/2019 | 9818.85% | JP Morgan | $43 → $22 | Downgrades | Overweight → Neutral |
| 09/27/2019 | 3957.71% | Goldman Sachs | $14 → $9 | Downgrades | Neutral → Sell |
| 09/16/2019 | 6662.85% | Jefferies | $32 → $15 | Downgrades | Buy → Hold |
| 06/04/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 05/30/2019 | 13425.7% | Roth Capital | → $30 | Initiates Coverage On | → Buy |
| 05/23/2019 | 18385.12% | Stifel | → $41 | Initiates Coverage On | → Buy |
| 01/23/2019 | 27853.11% | Mizuho | → $62 | Initiates Coverage On | → Buy |
What is the target price for Atara Biotherapeutics (ATRA)?
The latest price target for Atara Biotherapeutics (NASDAQ: ATRA) was reported by Goldman Sachs on November 10, 2023. The analyst firm set a price target for $0.50 expecting ATRA to rise to within 12 months (a possible 125.43% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?
The latest analyst rating for Atara Biotherapeutics (NASDAQ: ATRA) was provided by Goldman Sachs, and Atara Biotherapeutics maintained their sell rating.
When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?
While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a maintained with a price target of $3.00 to $0.50. The current price Atara Biotherapeutics (ATRA) is trading at is $0.22, which is out of the analyst's predicted range.